Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.71 EUR | +1.14% | -6.08% | +65.12% |
Apr. 08 | Sensorion: completion of a private placement | CF |
Apr. 05 | Sensorion SA announced that it expects to receive ?15 million in funding | CI |
Business Summary
Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation.
Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
Number of employees: 57
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 17-04-11 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 10 |
Géraldine Honnet
CTO | Chief Tech/Sci/R&D Officer | - | 20-02-17 |
Noémie Djokovic
IRC | Investor Relations Contact | - | - |
Judith Laredo
PRN | Corporate Officer/Principal | - | - |
Valerie Salentey
LAW | General Counsel | - | 20-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cédric Moreau
BRD | Director/Board Member | - | - |
Khalil Barrage
CHM | Chairman | 59 | - |
John Furey
BRD | Director/Board Member | 59 | 19-08-31 |
Florian Reinaud
BRD | Director/Board Member | 51 | - |
Director/Board Member | - | 15-03-08 | |
Aniz Girach
BRD | Director/Board Member | 56 | 22-01-02 |
Julien Miara
BRD | Director/Board Member | - | - |
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 17-04-11 |
Director/Board Member | 50 | Jan. 23 | |
Natalie Berner
BRD | Director/Board Member | 34 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 187,080,794 | 79,138,558 ( 42.30 %) | 0 | 42.30 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SENSORION 0.05% | 144,811 | 0.05% | 120,268 $ |
Company contact information
Sensorion SA
375, rue du Professeur Joseph Blayac
34080, Montpellier
+33 4 67 20 77 30
http://www.sensorion.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.12% | 206M | |
-1.78% | 41.36B | |
+45.60% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- ALSEN Stock
- Company Sensorion